Bridge to Life raised $110 million in August, but the number is less interesting than the sequencing. The company had already received FDA De Novo clearance for its VitaSmart liver-perfusion system in January. By the time the Series C and debt financing closed, the company was raising to expand commercial rollout and build its next products, not to find out whether its core system could clear its largest regulatory hurdle. Bridge to Life’s financing announcement makes that unusually explicit.
The financing question had changed
A lot of deeptech fundraising is still framed as a request for capital to get through the biggest unknown. Build the prototype. Run the trial. Obtain the clearance. Prove the manufacturing process. Win the first customer.
Sometimes that is unavoidable. The amount of capital required to reach the proof point is simply too large to self-fund or finance with a small seed round. But there is a major difference between raising before the critical evidence exists and raising after it does.
VitaSmart received FDA De Novo clearance on January 20, 2026. The company says that clearance was supported by a 219-recipient, 15-centre US clinical trial. The clearance announcement describes the system as the first FDA-cleared device for hypothermic oxygenated perfusion of donor livers.
Then, in August, Bridge to Life announced a $110 million Series C and debt financing led by Soleus Capital, with Lauxera Capital Partners and a credit vehicle also involved. The stated uses were commercial field expansion, working capital, debt refinancing and further product development. The company’s release says the product had already entered early commercial rollout.
That is a different investment proposition. Investors are still taking risk, but it is increasingly a question of adoption, sales execution, manufacturing, reimbursement and capital allocation. The hardest question is no longer, “Can this device be cleared?” It becomes, “Can this company turn a cleared device into a durable commercial business?”
Proof changes the price of capital
Founders sometimes talk about technical proof as if it matters only to customers or regulators. It matters just as much to the cost and character of capital.
A company that can show a signed purchase order, a completed trial, a clearance or a real production line is not simply more credible. It gives an investor more specific downside cases to assess. The investor can challenge conversion rates, reimbursement timelines, field-team productivity and gross margin assumptions. Those are difficult questions, but they are concrete ones.
The alternative is a much wider range of risk. Before a regulatory decision, the investor is underwriting the technology, the trial design, the quality system, the regulator, the commercial market and the team’s ability to navigate all of them. After the decision, the unknowns narrow.
That narrowing can attract a different kind of investor, and it can also support different forms of capital. Bridge to Life’s round includes both equity and debt. It would be a mistake to treat that as proof that any cleared company can or should use debt. Debt adds obligations and reduces room for error. But it does illustrate the broader point: once there is a cleared product and an early commercial business, the financing menu is wider than it was at the experimental stage.
Clearance is not the finish line
There is an important caveat here. FDA clearance is powerful evidence, but it is not a commercial guarantee.
Bridge to Life’s own announcement includes forward-looking commercial claims and says its commercial and clinical figures are preliminary and unaudited. It also describes its viability-assessment tool as investigational and not cleared for sale. Those qualifications appear in the release itself .
That is exactly why the financing sequence is interesting. The company has cleared one proof point. It now has to meet a different one: repeat adoption by transplant centres, reliable delivery, a sales organisation that can reach a specialised market, and economic evidence that stands up outside the company’s own materials.
Many technically strong companies stumble here because they treat clearance as a finish line instead of a change in the work. It is better understood as a handoff. Clinical and regulatory execution hand the company to commercial execution, and the people, metrics and capital needs change with it.
The founder’s question
The practical takeaway is not that every founder should wait to raise until the hardest proof point is complete. That can be financially impossible, and waiting too long can create its own risk.
The better question is: what would make the next round about scale rather than belief?
For a medical device, it may be a clearance and a small group of live clinical customers. For an industrial technology company, it may be a paid production deployment. For a robotics company, it may be a machine operating through a full customer cycle with measured uptime. The proof point changes by category, but the financing logic does not.
Bridge to Life’s $110 million is a useful reminder that the strongest growth round is often not the one that funds the first hard proof. It is the one that arrives after the company has already made the hardest part easier to believe.
That distinction is worth keeping in mind when evaluating what counts as a checkable claim versus a checked one . Capital will fund a promise. It just prices the promise very differently from evidence.
Clement Chen is a startup founder, advisor, and investor who writes about deeptech and building companies at clementchen.co .